ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COCP Cocrystal Pharma Inc

1.48
0.00 (0.00%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 1.34
Ask Price 1.60
News -
Day High

Low
1.325

52 Week Range

High
3.285

Day Low
Company Name Stock Ticker Symbol Market Type
Cocrystal Pharma Inc COCP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.48 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.48
Trades Volume Avg Volume 52 Week Range
0 0 - 1.325 - 3.285
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.48 USD

Cocrystal Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
15.06M 10.17M - 0 -38.84M -3.82 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cocrystal Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No COCP Message Board. Create One! See More Posts on COCP Message Board See More Message Board Posts

Historical COCP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.431.561.4161.4812,9110.053.50%
1 Month1.471.581.3251.4813,3160.010.68%
3 Months1.791.891.3251.5812,291-0.31-17.32%
6 Months2.002.181.3251.7216,384-0.52-26.00%
1 Year1.873.2851.3252.2134,203-0.39-20.86%
3 Years18.0041.521.32519.131,864,054-16.52-91.78%
5 Years34.5649.201.32518.872,049,098-33.08-95.72%

Cocrystal Pharma Description

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Your Recent History

Delayed Upgrade Clock